Physician profile
Robert Christopher Hancock
NPI 1518975408
$1,174.09
in general payments reported to CMS, 2019-2025
13 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $29.01 · 2021: $247 · 2022: $73.76 · 2023: $257 · 2024: $351 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $563.69 | 2020-2025 | Stravix Pl, Grafix Pl, Stravix |
| Organogenesis INC. | $275.51 | 2021-2022 | |
| Progenacare Global, LLC | $79.88 | 2023 | |
| Zyla Life Sciences, INC. | $64.96 | 2019 | |
| Paratek Pharmaceuticals, INC. | $48.67 | 2023-2024 | Nuzyra |
| Medtronic, INC. | $27.39 | 2025 | Intellis Adaptivestim |
| Nevro Corp. | $25.25 | 2023 | Senza |
| Abbott Laboratories | $18.43 | 2025 | Eterna |
| Musculoskeletal Transplant Foundation INC. | $15.09 | 2019 | |
| Allergan, INC. | $14.75 | 2019 | |
| Abbvie INC. | $13.73 | 2021 | |
| Averitas Pharma INC. | $13.41 | 2023 | Qutenza |
| Bioventus LLC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.